Combination Therapy of Simeprevir and Sofosbuvir in Recurrent HCV Genotype 4 After Liver Retransplantation: Case Report
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Unexpected drug reaction
Aiman Obed, Anwar Jarrad, Abdalla Bashir, Gero Moog
(Department of Hepatobiliary and Transplant Surgery, Jordan Hospital, Amman, Jordan)
Am J Case Rep 2016; 17:357-359
The treatment of hepatitis C virus (HCV) infection is evolving rapidly. Many studies have been completed during the last 2 years, with more studies still in progress. The management of recurring HCV infection following liver organ transplantation remains very challenging, especially for HCV genotype 4 (GT-4). More research is needed in this area.
CASE REPORT: We report on a patient with a recurring HCV infection and fibrosing cholestatic hepatitis following liver retransplantation, who was successfully treated with a combination therapy of simeprevir and sofosbuvir without interferon/ribavirin. As far as we know, this is the first reported case of this kind.
CONCLUSIONS: This information may be of importance and inform future management of patients with recurrent HCV infections following liver transplantation.
Keywords: Drug Therapy, Combination, Antiviral Agents - therapeutic use, Genotype, Hepacivirus - genetics, Hepatitis C, Chronic - drug therapy, Humans, Liver Transplantation, Male, Middle Aged, Reoperation, Simeprevir - therapeutic use, Sofosbuvir - therapeutic use